Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Aerie Rockets as Eye Drug Wows in Key Phase III Study

Shares of Aerie Pharmaceuticals were soaring more than 35 percent after the company announced Phase III data for its combination glaucoma drug, Roclatan, met efficacy endpoints.

Read More »

Under U.S. Republican bill, 23 million would lose health coverage: watchdog

A bill passed by U.S. House Republicans would cause 23 million people to lose healthcare coverage by 2026 while de-stabilizing health insurance markets in some states and making it hard for sick people to buy insurance, a budget watchdog agency said.

Read More »

FDA clears Keytruda based on cancer genetics

Merck & Co.’s Keytruda became the first cancer drug FDA-approved based on a patients’ specific genetic traits regardless of where in the body the disease originated.

Read More »

FDA to review Opdivo for HCC indication

The U.S. FDA accepted a supplemental BLA that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma after prior sorafenib therapy.

Read More »

26 Patients Dead After Replacing Controller for Abbott’s HeartMate II Blood Pumps at Home

Abbott Laboratories is recalling for more than 28,000 of its HeartMate II blood pumps after 26 patients died after attempting to exchange controllers while away from the hospital.

Read More »

tranSMART Foundation Teams With IBM to Bring Translational Medicine Data to Scientists, Merges With I2B2

Biotech researchers looking to harness the power of big data could have an easier time with the new partnership between IBM and the tranSMART Foundation, a Massachusetts-based nonprofit organization founded in 2012 with a goal of providing a platform to share pre-competitive data for use in designing transformational medicines.

Read More »

Novartis to Lay Off 250 Nationwide, With 204 from New Jersey U.S. Headquarters

Novartis AG, headquartered in Basel, Switzerland, filed with the state of New Jersey that it plans to lay off more than 200 workers. The company, whose U.S. headquarters are in East Hanover, NJ, is undergoing operational changes.

Read More »

Neurocrine Tanks as Tourette Syndrome Drug Flunks Mid-Stage Study

Shares of Neurocrine Biosciences Inc. were down more than 8 percent after its Phase II Tourette syndrome drug Ingrezza (valbenazine) failed to meet its primary endpoint due to what the company said was inadequate dosing.

Read More »

UK biotech boasts Europe’s best pipeline as Brexit threat looms

Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.

Read More »

Massive FDA and NIH Cuts in Trump’s Outlined Budget Plan

President Donald Trump’s 2018 budget proposal takes a machete to the spending plans of nationally funded health programs that fund medical research, disease prevention and insurance plans.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom